Pieris Pharmaceuticals to Host Q1 2022 Investor Call and Provide Company Update on May 11, 2022

BOSTON,MA / ACCESSWIRE / May 42022 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS)a clinical-stage biotechnology company advancing novel biotherapies through its proprietary Anticalin® technology platform for respiratory disease, cancer and other indications, today announced that it will host an investor call for the first quarter 2022 on Wednesday, May 11, 2022 at 8:00 a.m. EDT to discuss financial results and provide a company update.

To access the call, participants can dial (888) 428-7458 (toll-free in the United States and Canada) or (862) 298-0702 (international) at least five minutes before the start of the session. call. Alternatively, a listen-only audio webcast of the call can be viewed here.

For those unable to participate in the conference call or listen to the webcast, a replay will be available in the Investors section of the Company’s website, www.pieris.com.

About Pieris Pharmaceuticals:

Pieris is a clinical-stage biotechnology company that combines cutting-edge protein engineering capabilities with a deep understanding of the molecular drivers of disease to develop drugs that drive local biology to produce superior clinical outcomes for patients. Our pipeline includes inhalable Anticalin proteins to treat respiratory diseases and locally activated bispecifics for immuno-oncology. Proprietary to Pieris, Anticalin proteins are a new class of clinically validated therapeutics and through respiratory and immuno-oncology focused partnerships with leading pharmaceutical companies. For more information, visit www.pieris.com.

Forward-looking statements:

This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release that are not purely historical are forward-looking statements. These forward-looking statements include, among others, the potential of Pieris’ development programs such as PRS-060/AZD1402, cinrebafusp alfa, PRS-344/S095012 and PRS-220 to address our key areas of interest such as respiratory diseases and immunological -oncology; the receipt of royalties provided for in our collaboration agreements; the progress of our proprietary and co-development programs in and across the clinic and the expected timeline for reporting data; make IND filings or achieve other milestones related to our programs, including PRS-060/AZD1402, cinrebafusp alfa, PRS-344/S095012, PRS-352, and PRS-220; and the expected timing of initiation of the next stage of cinrebafusp alfa’s development in gastric cancer. Actual results could differ from those projected in any forward-looking statement due to numerous factors. These factors include, among others, our ability to raise the additional funds we will need to continue to pursue our business and product development plans; the inherent uncertainties associated with developing new products or technologies and operating as a development-stage business; our ability to develop, conduct clinical trials, obtain approvals and commercialize any of our product candidates, including our ability to recruit and enroll patients in our studies; competition in the industry in which we operate; delays or disruptions due to COVID-19 or geopolitical issues, including the conflict in Ukraine; and market conditions. These forward-looking statements are made as of the date of this press release, and we undertake no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. , except as required by law. Investors should review all information set forth herein and should also refer to the disclosure of risk factors set forth in reports and other documents we file with the Securities and Exchange Commission available at www.sec.gov, including , without limitation, the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and Quarterly Reports on Form 10-Q.

Contact with Investor Relations:

Pieris Pharmaceuticals, Inc.

Maria Kelman

Executive Director, Investor Relations

+1 857 362 9635

[email protected]

THE SOURCE: Pieris Pharmaceuticals, Inc.

See the source version on accesswire.com:

Comments are closed.